BR112013029417A2 - composições de vacina de matriz proteica incluindo policátions - Google Patents
composições de vacina de matriz proteica incluindo policátionsInfo
- Publication number
- BR112013029417A2 BR112013029417A2 BR112013029417A BR112013029417A BR112013029417A2 BR 112013029417 A2 BR112013029417 A2 BR 112013029417A2 BR 112013029417 A BR112013029417 A BR 112013029417A BR 112013029417 A BR112013029417 A BR 112013029417A BR 112013029417 A2 BR112013029417 A2 BR 112013029417A2
- Authority
- BR
- Brazil
- Prior art keywords
- polycations
- protein matrix
- interest
- methods
- compositions including
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 239000011159 matrix material Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 108010078791 Carrier Proteins Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000000717 retained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
abstract the present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration. _____________________________________________________________________________________________________________________________________________________________________________________________ tradução do resumo resumo patente de invenção: "composições de vacina de matriz proteica incluindo policátions". a presente invenção refere-se a composições imunogênicas contendo um ou mais antígenos de interesse, uma ou mais proteínas carre-adoras, assim como um ou mais policátions, em que o antígeno de interesse é retido com a matriz proteica carreadora reticulada e um ou mais policá-tions, métodos de preparo de tais vacinas, e métodos para administração da vacina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161487663P | 2011-05-18 | 2011-05-18 | |
US61/487,663 | 2011-05-18 | ||
PCT/US2012/037961 WO2012158701A1 (en) | 2011-05-18 | 2012-05-15 | Protein matrix vaccine compositions including polycations |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013029417A2 true BR112013029417A2 (pt) | 2017-01-31 |
BR112013029417B1 BR112013029417B1 (pt) | 2022-10-25 |
Family
ID=47177310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013029417-5A BR112013029417B1 (pt) | 2011-05-18 | 2012-05-15 | Composições de vacina de matriz proteica incluindo policátions e método de preparo das mesmas |
Country Status (14)
Country | Link |
---|---|
US (1) | US9724401B2 (pt) |
EP (2) | EP2709656B1 (pt) |
JP (1) | JP6072777B2 (pt) |
KR (1) | KR101670340B1 (pt) |
CN (1) | CN103747798B (pt) |
AU (1) | AU2012255878B2 (pt) |
BR (1) | BR112013029417B1 (pt) |
CA (1) | CA2836251C (pt) |
DK (1) | DK2709656T3 (pt) |
ES (1) | ES2728653T3 (pt) |
HK (1) | HK1197033A1 (pt) |
MX (1) | MX349657B (pt) |
WO (1) | WO2012158701A1 (pt) |
ZA (1) | ZA201309516B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10500283B2 (en) * | 2011-05-30 | 2019-12-10 | National Institute Of Immunology | Vaccine composition capable of inducing memory antibody response from single point immunization |
EP2946010B1 (en) | 2013-01-18 | 2018-08-29 | London School of Hygiene and Tropical Medicine | Glycosylation method |
GB201301085D0 (en) * | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
RU2743793C1 (ru) * | 2014-01-21 | 2021-02-26 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
CN104548090B (zh) * | 2015-01-27 | 2016-11-30 | 中国科学院过程工程研究所 | 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法 |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
JP2020536968A (ja) | 2017-10-13 | 2020-12-17 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 共生疾患進行に対する包括的ワクチン設計 |
CA3084436A1 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2107106A1 (en) | 1991-03-28 | 1992-09-29 | Jo Klaveness | Cross-linking agent |
AU755502C (en) | 1999-03-24 | 2003-08-14 | Secretary Of State For Defence, The | Immunostimulants |
AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
PT1701968E (pt) | 2003-12-17 | 2015-09-11 | Wyeth Llc | Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos |
WO2008021076A2 (en) | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Protein matrix vaccines and methods of making and administering such vaccines |
ZA200900899B (en) * | 2006-08-07 | 2010-07-28 | Harvard College | Protein matrix vaccines and methods of making and administering such vaccines |
US20090142362A1 (en) | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
US20100226987A1 (en) | 2007-06-28 | 2010-09-09 | Capsutech Ltd. | Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers |
EP2473188A4 (en) | 2009-09-09 | 2014-01-01 | Matrivax Res & Dev Corp | PROTEIN MATRIX VACCINES WITH IMPROVED IMMUNOGENICITY |
WO2011036560A2 (en) * | 2009-09-23 | 2011-03-31 | Novartis Ag | Glycoconjugate compositions and methods for treatment of hiv |
-
2012
- 2012-05-15 CN CN201280028850.1A patent/CN103747798B/zh active Active
- 2012-05-15 ES ES12786365T patent/ES2728653T3/es active Active
- 2012-05-15 WO PCT/US2012/037961 patent/WO2012158701A1/en active Application Filing
- 2012-05-15 MX MX2013013358A patent/MX349657B/es active IP Right Grant
- 2012-05-15 EP EP12786365.2A patent/EP2709656B1/en active Active
- 2012-05-15 US US14/118,552 patent/US9724401B2/en active Active
- 2012-05-15 JP JP2014511458A patent/JP6072777B2/ja active Active
- 2012-05-15 BR BR112013029417-5A patent/BR112013029417B1/pt not_active IP Right Cessation
- 2012-05-15 AU AU2012255878A patent/AU2012255878B2/en active Active
- 2012-05-15 DK DK12786365.2T patent/DK2709656T3/da active
- 2012-05-15 CA CA2836251A patent/CA2836251C/en active Active
- 2012-05-15 EP EP19165038.1A patent/EP3524265A1/en not_active Withdrawn
- 2012-05-15 KR KR1020137033549A patent/KR101670340B1/ko active IP Right Grant
-
2013
- 2013-12-17 ZA ZA2013/09516A patent/ZA201309516B/en unknown
-
2014
- 2014-10-22 HK HK14110560.3A patent/HK1197033A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012255878A1 (en) | 2013-05-02 |
HK1197033A1 (en) | 2015-01-02 |
US9724401B2 (en) | 2017-08-08 |
MX349657B (es) | 2017-08-08 |
DK2709656T3 (da) | 2019-06-24 |
AU2012255878B2 (en) | 2016-05-12 |
CA2836251A1 (en) | 2012-11-22 |
KR101670340B1 (ko) | 2016-10-28 |
CN103747798A (zh) | 2014-04-23 |
KR20140045416A (ko) | 2014-04-16 |
EP2709656A4 (en) | 2015-01-14 |
BR112013029417B1 (pt) | 2022-10-25 |
MX2013013358A (es) | 2014-07-09 |
WO2012158701A1 (en) | 2012-11-22 |
EP2709656A1 (en) | 2014-03-26 |
US20140086989A1 (en) | 2014-03-27 |
JP2014513726A (ja) | 2014-06-05 |
EP2709656B1 (en) | 2019-03-27 |
ES2728653T3 (es) | 2019-10-28 |
ZA201309516B (en) | 2017-04-26 |
EP3524265A1 (en) | 2019-08-14 |
CA2836251C (en) | 2017-07-04 |
JP6072777B2 (ja) | 2017-02-01 |
CN103747798B (zh) | 2018-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
BR112016013493A2 (pt) | molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo | |
BR112012027055A2 (pt) | agente estabilizante para proteínas farmacêuticas. | |
BR112013030894A2 (pt) | moduladores do sistema imune | |
BR112012022669A2 (pt) | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. | |
BR112014026531A2 (pt) | proteínas de ligação de antígeno ligando cd30 humano | |
BR112013026661A2 (pt) | método de entrega de vacina | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
BR112016004108A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit | |
BR112012030616A2 (pt) | concentração de antígenos de vacina com liofilização. | |
BR112017000519A2 (pt) | "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112015012711A2 (pt) | método de produção de uma vacina de mycoplasma | |
BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
BR112014001409A2 (pt) | métodos e composições para vacinação contra staphylococcus aureus | |
BR112012030619A2 (pt) | concentração de antígenos de vacina influenza sem liofilização. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |